文献速递真菌感染细菌感染、耐药与抗菌药物

新型抗真菌药olorofim对皮肤癣菌及机会性霉菌的体外活性

In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

本研究采用CLSI微量肉汤稀释法,检测olorofim对来自印度北部的241株霉菌临床分离株的体外活性,并与五种系统性唑类、两性霉素B、特比萘芬和卢立康唑比较。结果显示olorofim对皮肤癣菌和机会性霉菌(除链格孢外)具有高效体外活性,包括特比萘芬耐药和唑类耐药的毛癣菌及唑类耐药烟曲霉。

要点

  • Olorofim对皮肤癣菌和机会性霉菌MIC范围为0.004-0.125 mg/L,但对链格孢无活性。
  • 对特比萘芬耐药和唑类耐药的毛癣菌,olorofim模态MIC为0.008 mg/L。
  • 对唑类耐药烟曲霉(Cyp51A突变)及隐种曲霉,olorofim MIC范围为0.004-0.03 mg/L。

核心结论

  • Olorofim对耐药皮肤癣菌和机会性霉菌表现出强效体外活性,值得评估其临床效用。

研究设计与样本

  • 采用CLSI微量肉汤稀释法,检测olorofim对241株霉菌临床分离株的体外抗真菌敏感性。
  • 分离株包括曲霉属、假阿利什霉属、链格孢、皮肤癣菌(含特比萘芬耐药和多重耐药毛癣菌)及青霉/篮状菌属,来自印度北部患者。
  • 对照药物为五种系统性唑类、两性霉素B、特比萘芬和卢立康唑。

主要发现

  • Olorofim对皮肤癣菌和机会性霉菌总体MIC范围为0.004-0.125 mg/L,但对链格孢无体外活性。
  • 青霉属和篮状菌属及毛癣菌属的olorofim几何平均MIC分别为0.027 mg/L和0.015 mg/L。
  • 与唑类相比,olorofim对青霉属和篮状菌属的体外活性低2-12个稀释倍数。
  • 对特比萘芬耐药和唑类耐药的须癣毛癣菌/指间毛癣菌,olorofim模态MIC为0.008 mg/L。
  • 对Cyp51A突变唑类耐药烟曲霉及隐种曲霉,olorofim MIC范围为0.004-0.03 mg/L。

临床怎么用

  • 对于特比萘芬或唑类耐药的皮肤癣菌感染,olorofim可能是有前景的治疗选择,但需临床研究验证。
  • 对唑类耐药烟曲霉及隐种曲霉感染,olorofim体外活性良好,可作为潜在治疗选项。
  • 链格孢感染不建议使用olorofim,因其无体外活性。

局限性

  • 仅为体外研究,尚未评估临床疗效和安全性。
  • 分离株仅来自印度北部患者,代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Olorofim is a novel antifungal agent with in vitro activity against Aspergillus and other opportunistic moulds. We investigated the in vitro activity of olorofim against a range of filamentous fungi comprising isolates of Aspergillus species, Scedosporium species, Alternaria alternata, dermatophytes, including terbinafine- and multidrug-resistant Trichophyton species, and Penicillium/Talaromyces species originating from patients in North India. METHODS: Antifungal susceptibility of olorofim was tested against 241 mould isolates of Penicillium/Talaromyces species, Trichophyton species, A. fumigatus and cryptic Aspergillus species, Scedosporium species, and Alternaria alternata using CLSI broth microdilution. The comparators were five systemic azoles, amphotericin B, terbinafine, and luliconazole. RESULTS: Overall, olorofim showed highly potent in vitro activity against dermatophytes and opportunistic moulds (MIC range of 0.004-0.125 mg/L) except for Alternaria alternata. Penicillium, and Talaromyces species and Trichophyton species exhibited a low geometric mean (GM) MIC (GM 0.027 mg/L and 0.015 mg/L, respectively) of olorofim. Importantly, a 2-12 dilution step decrease in in vitro activity of olorofim as compared with azoles was observed against Penicillium and Talaromyces. Notably, olorofim displayed potent in vitro activity against Trichophyton isolates including terbinafine-resistant and azole-resistant Trichophyton mentagrophytes/interdigitale with a modal MIC value of 0.008 mg/L. Further, azole-resistant A. fumigatus isolates harbouring mutations in azole target Cyp51A genes and several cryptic aspergilli displayed low MICs (range 0.004-0.03 mg/L) of olorofim. However, no in vitro activity of olorofim against Alternaria alternata was observed. CONCLUSIONS: The potent in vitro activity of olorofim against drug-resistant dermatophytes and opportunistic moulds is promising, warranting evaluation of the clinical utility of olorofim.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Singh A, Singh P, Meis JF, et al. In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species. J Antimicrob Chemother. 2021. PMID: 33421073. doi:10.1093/jac/dkaa562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。